A final analysis of the Phase 3 trial of Pfizer's vaccine shows it was 95% effective in preventing infections, even in older adults, and caused no serious safety concerns, the company said last month. Pfizer CEO Albert Bourla called the emergency authorization as "a historic moment in the fight against Covid-19."